Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor... see more

Recent & Breaking News (OTCQB:NWBO)

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

PR Newswire July 3, 2024

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

PR Newswire June 17, 2024

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

PR Newswire March 21, 2024

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

PR Newswire February 6, 2024

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

PR Newswire December 21, 2023

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

PR Newswire November 22, 2023

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

PR Newswire October 13, 2023

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

PR Newswire September 12, 2023

Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application

PR Newswire August 29, 2023

Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

PR Newswire March 20, 2023

Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB

PR Newswire March 11, 2023

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

PR Newswire January 6, 2023

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

PR Newswire November 17, 2022

Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA

PR Newswire August 23, 2022

Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility

PR Newswire July 6, 2022

Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program

PR Newswire June 5, 2022

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

PR Newswire May 10, 2022

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

PR Newswire May 4, 2022

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

PR Newswire February 17, 2022

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

PR Newswire December 21, 2021